Table 4.
Real-time polymerase chain reaction studies showing the gene expression of various genes when treated with LPS and anti-inflammatories/cytoprotectants
| IL-1β | IL-6 | TNF-α | MMP-2 | MMP-3 | ADAMTS-5 | IL-2 | IL-10 | CYT-C | IGF1R | COL9A1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | 0.0068 | 0.63 | 2.04 | 1,000.34 | 0.68 | 0.27 | 0.04 | 0.14 | 0.05 | 1.63 | 35,997.90 |
| LPS | 2,002.069 | 33,456.5 | 2,142.0562 | 19,483.96 | 4,544.79 | 68,556.22 | 254,975.65 | 63,303.6 | 2,476,721.12 | 8,220.44 | 256,789.00 |
| Curvularin | 0.097 | 6,555.08 | 11.05 | 15,545.16 | 0.00 | 60,500.13 | 0.00 | 0.00 | 0.00 | 0.00 | 348,942.77 |
| Betamethasone | 0.085 | 2.63 | 7.87 | 1,300.01 | 5,001.87 | 0.01 | 0.01 | 0.32 | 990,000.19 | 0.03 | 318,326.58 |
| Dexamethasone | 0.080 | 0.92 | 8.21 | 1,350.13 | 5,000.71 | 60,000.34 | 0.08 | 0.05 | 900,000.03 | 0.08 | 316,970.68 |
| Combination | 0.070 | 0.15 | 5.28 | 1,000.20 | 0.25 | 50,000.11 | 0.29 | 0.08 | 350,000.01 | 0.24 | 32,894.56 |
LPS, lipopolysaccharide; IL, interleukin; TNF, tumor necrosis factor; MMPs, matrix metalloproteinases; CYT-C, cytochrome c; IGF1R, insulin-like growth factor 1 receptor; COL9A1, collagen 9 alpha 1.